Tectonic CFO granted 24,250 options at $29.92

Tectonic Therapeutic’s CFO received a 24,250-share stock option grant with staged vesting through 2030.

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. (TECX) reported that Chief Financial Officer Daniel Lochner received a grant of 24,250 employee stock options on September 3, 2026. The options have an exercise price of $29.92 per share and expire on September 2, 2036. According to the vesting terms, 1/8 vests on September 3, 2026, with the remaining shares vesting in 42 equal monthly installments beginning October 3, 2026, subject to his continued service.

Insider Trade Summary

Grant/Award: 24,250 shares

Grant/Award 1 txn

Insider Lochner Daniel

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy) F1	24,250	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 24,250 contracts (Direct)

Footnotes (1)

1. F1. 1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Options granted: 24,250 options Exercise price: $29.92 per share Expiration date: September 2, 2036 +2 more

5 metrics

Options granted 24,250 options Employee stock option grant to CFO on September 3, 2026

Exercise price $29.92 per share Exercise price of the employee stock options granted to the CFO

Expiration date September 2, 2036 Option expiration for the CFO’s employee stock options

Initial vesting portion 1/8 of granted options Vests on September 3, 2026, per vesting footnote

Remaining vesting period 42 monthly installments Remaining options vest monthly beginning October 3, 2026

Key Terms

Employee Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Employee Stock Option (Right to Buy) financial

"security title is listed as Employee Stock Option (Right to Buy)"

exercise price financial

"conversion or exercise price is reported as 29.9200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the option vest on September 3, 2026"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration date for the option is September 2, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

What insider transaction did TECX disclose for its CFO?

Tectonic Therapeutic disclosed that Chief Financial Officer Daniel Lochner received a grant of 24,250 employee stock options on September 3, 2026, giving him the right to buy common shares at a fixed exercise price if and when the options vest.

What is the exercise price of the new TECX stock options granted to the CFO?

The employee stock options granted to Tectonic Therapeutic’s CFO have an exercise price of $29.92 per share. This is the price at which he may purchase common stock upon exercise of vested options, subject to the vesting schedule and option terms.

How many TECX options did the CFO hold after this reported grant?

After the reported grant, Chief Financial Officer Daniel Lochner held 24,250 stock options related to this award, as shown by the total derivative securities beneficially owned following the transaction on the Form 4.

What is the vesting schedule for the TECX options granted to the CFO?

According to the footnote, 1/8 of the options vest on September 3, 2026. The remaining shares vest in 42 equal monthly installments beginning on October 3, 2026, subject to the CFO’s continued service to the company on each vesting date.

When do the newly granted TECX stock options expire?

The stock options granted to Tectonic Therapeutic’s CFO on September 3, 2026 carry an expiration date of September 2, 2036, after which any unexercised options will no longer be exercisable.

Were the TECX CFO’s option grants made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not checked, and there is no footnote describing a trading plan, so these option grants are reported without reference to a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:45 PM Accepted by SEC EDGAR 09/08/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lochner Daniel

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$29.92	09/03/2026		A		24,250		(1)	09/02/2036	Common Stock	24,250	$0	24,250	D

Explanation of Responses:

1. 1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Daniel Lochner	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)